Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib Followed by Nivolumab in Advanced Hepatocellular Carcinoma (GOING)
NCT04170556Phase 2Completed
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Mar 2020
- Primary completion
- Jul 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib and nivolumab in hepatocellular carcinoma (HCC), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoints: Incidence of Treatment-Emergent Adverse Events up to 24 months and Incidence of related Treatment-Emergent Adverse Events up to 24 months. Started Mar 2020; status: completed.
02
Drugs
regorafenibnivolumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04170556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04170556.